GeoVax Q3 net loss $3.97M; cash jumps to $34.7M; Phase 2 trials advance

GeoVax Labs, Inc.

Net loss $3.97M ($0.17/sh) for Q3 2022 vs $1.95M ($0.31) in Q3 2021; 9-month net loss $8.64M.
Cash $34.7M at Sep 30, 2022 vs $11.4M at Dec 31, 2021; raised $27.7M from stock/warrant sales and $7.6M from warrant exercises.
Phase 2 COVID vaccine GEO-CM04S1 advancing; Lancet Microbe data show robust neutralizing antibodies and T cells; expanding sites.
Gedeptin Phase 1/2 for head and neck cancer expands to Emory and Thomas Jefferson; FDA orphan grant funded.
Secured rights to NIH-MVA for monkeypox/smallpox; began preclinical studies for pan-coronavirus and MUC1 immunotherapy.

item 2.02 item 7.01 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.9

GeoVax Labs, Inc. reported financial results for the third quarter ended September 30, 2022.

Period: the third quarter ended September 30, 2022
Result: reported results

Exact text from the filing

On November 9, 2022, GeoVax Labs, Inc. (the “Company”) issued a press release reporting its results of operations for the quarter ended September 30, 2022.

View on SEC.gov

3 earnings releases filed in the last 30 days. Browse all earnings releases →

GeoVax Labs, Inc. filing history →

Source: SEC EDGAR

accession 0001437749-22-027003

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.